Aspirin (Synonyms: 阿司匹林; Acetylsalicylic Acid; ASA)

目錄號(hào): HY-14654 純度: 99.82%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南

摩爾計(jì)算器

Aspirin (Acetylsalicylic Acid) 是一種口服有效的不可逆的環(huán)氧合酶 COX-1 和 COX-2 抑制劑，IC₅₀ 分別為 5 和 210 μg/mL. Aspirin 誘導(dǎo)細(xì)胞凋亡 (apoptosis)。Aspirin 可抑制 NF-κB 的活化。Aspirin 還抑制血小板前列腺素合成酶 (prostaglandin synthetase)，可預(yù)防冠狀動(dòng)脈和腦血管血栓形成。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Aspirin Chemical Structure

CAS No. : 50-78-2

1. 客戶(hù)無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶(hù)。

規(guī)格	價(jià)格	是否有貨
10 mM * 1 mL in DMSO	￥500	In-stock
500 mg	￥400	In-stock
1 g	￥500	In-stock
5 g	￥800	In-stock
10 g		詢(xún)價(jià)
50 g		詢(xún)價(jià)

or 大包裝詢(xún)價(jià)

* Please select Quantity before adding items.

Customer Review

Other Forms of Aspirin:

Aspirin-d₃ In-stock
Aspirin-d₄ In-stock
Aspirin Aluminum In-stock
Aspirin (Standard) In-stock
Aspirin lithium 詢(xún)價(jià)
Aspirin calcium 詢(xún)價(jià)

MCE 顧客使用本產(chǎn)品發(fā)表的 21 篇科研文獻(xiàn)

•Cell Host Microbe. 2024 Feb 14;32(2):191-208.e9. [Abstract]
•Nat Commun. 2024 Sep 10;15(1):7914. [Abstract]
•Cancer Res. 2018 Oct 1;78(19):5586-5599. [Abstract]
•Cell Prolif. 2022 Dec 10;e13380. [Abstract]
•Acta Pharmacol Sin. 2021 Apr 6. [Abstract]
•Cell Death Dis. 2018 Aug 28;9(9):847. [Abstract]

•Mol Med. 2024 Aug 16;30(1):126. [Abstract]
•Mol Nutr Food Res. 2024 Aug 1:e2400307. [Abstract]
•Front Cell Dev Biol. 2023 Sep 8;11:1266198. [Abstract]
•Food Chem Toxicol. 2023 Jun 24;113919. [Abstract]
•Int J Mol Sci. 2022, 23(16), 9118.
•Front Pharmacol. 2022 Jan 10;12:792263. [Abstract]
•Front Immunol. 01 December 2021.
•J Appl Toxicol. 2024 Jun 5. [Abstract]
•PLoS One. 2023 May 19;18(5):e0285216. [Abstract]
•Neurotoxicology. 2021 Dec 31;S0161-813X(21)00170-4. [Abstract]
•ACS Omega. 2020 Aug 4;5(32):19995-20003. [Abstract]
•Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7381-7390. [Abstract]
•NPJ Sci Food. 2022 Dec 5;6(1):55. [Abstract]
•Oxid Med Cell Longev. 2022 Feb 9;2022:4295208. [Abstract]
•STAR Protoc. 17 September 2021, 100787.

: Aspirin purchased from MCE. Usage Cited in: Cell Death Dis. 2018 Aug 28;9(9):847. [Abstract]; HIPK2 expression is upregulated by treatments with 5?μM Resveratrol, 30?μM Aspirin, 10?μM Vitamin E, and 15?μM Ursolic acid for another 16?h after the LPS treatment, as analysed by western blotting.

Aspirin 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 COX 亞型特異性產(chǎn)品:

查看所有亞型

COX COX-1 COX-2 COX-3

查看 NF-κB 亞型特異性產(chǎn)品:

查看所有亞型

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

查看 Caspase 亞型特異性產(chǎn)品:

查看所有亞型

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

查看 p38 MAPK 亞型特異性產(chǎn)品:

查看所有亞型

p38 MAPK p38α p38β MAPK13 p38δ p38γ

生物活性
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Aspirin (Acetylsalicylic Acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC₅₀ values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis^[1]^[2]^[3]^[4]^[5]^[6].

IC₅₀ & Target^[1]

COX-1

27.75 μM (IC₅₀)

COX-2

1.17 mM (IC₅₀)

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 22916316]
Bel-7402	IC₅₀	> 100 μM Compound: Aspirin	Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
Bel7402/5-FU	IC₅₀	> 100 μM Compound: Aspirin	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
BGC-823	IC₅₀	> 50 μM Compound: Aspirin	Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
BXPC-3	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against human BxPC3 cells expressing COX1 and COX2 after 24 hrs by MTT assay Cytotoxicity against human BxPC3 cells expressing COX1 and COX2 after 24 hrs by MTT assay	[PMID: 22916316]
Caco-2	IC₅₀	> 50 μM Compound: Aspirin	Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
DLD-1	IC₅₀	> 100 μM Compound: 1; ASA	Antiproliferative activity against human DLD1 cells after 72 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 72 hrs by MTT assay	[PMID: 30429977]
DU-145	IC₅₀	> 100 μM Compound: 1; ASA	Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
Erythrocyte	IC₅₀	166 mM Compound: Aspirin	Antiinflammatory activity in human erythrocytes assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometry Antiinflammatory activity in human erythrocytes assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometry	[PMID: 25638040]
HaCaT	IC₅₀	21.27 μM Compound: ASA	Antiinflammatory activity against human HaCaT cells assessed as inhibition of UVB irradiation-induced PGE2 production measured after 2 hrs by ELISA Antiinflammatory activity against human HaCaT cells assessed as inhibition of UVB irradiation-induced PGE2 production measured after 2 hrs by ELISA	[PMID: 35172097]
HaCaT	IC₅₀	30.4 μM Compound: Aspirin	Inhibition of ultraviolet B-irradiation upregulated of prostaglandin E2 production in human HaCaT cells measured after 2 hrs by ELISA Inhibition of ultraviolet B-irradiation upregulated of prostaglandin E2 production in human HaCaT cells measured after 2 hrs by ELISA	[PMID: 34463498]
HCT-116	IC₅₀	> 60 μM Compound: 3	Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
HCT-15	IC₅₀	> 5000000 nM Compound: Aspirin	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HCT15 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 26323873]
HCT-15	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against COX deficient human HCT15 cells after 24 hrs by MTT assay Cytotoxicity against COX deficient human HCT15 cells after 24 hrs by MTT assay	[PMID: 22916316]
HCT-8	IC₅₀	> 100 μM Compound: 1; ASA	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 30429977]
HCT-8	IC₅₀	> 100 μM Compound: 2; ASA	Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 30037494]
HCT-8	IC₅₀	15.6 μM Compound: 2; ASA	Antiproliferative activity against human HCT8 cells after 72 hrs in presence of cinnamaldehyde by MTT assay Antiproliferative activity against human HCT8 cells after 72 hrs in presence of cinnamaldehyde by MTT assay	[PMID: 30037494]
HEK293	IC₅₀	10.2 mM Compound: 4	Cytotoxicity against HEK293 cells harboring pendrin P123S mutant after 72 hrs by MTT assay Cytotoxicity against HEK293 cells harboring pendrin P123S mutant after 72 hrs by MTT assay	[PMID: 28341401]
HepG2	IC₅₀	3841 μM Compound: Aspirin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23153797]
HT-29	IC₅₀	> 100 μM Compound: 1; ASA	Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
HT-29	EC₅₀	> 1000 μM Compound: ASA	Apoptosis induction in human HT29 cells after 24 hrs Apoptosis induction in human HT29 cells after 24 hrs	[PMID: 17441704]
HT-29	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	> 5000000 nM Compound: Aspirin	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 26323873]
HT-29	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against human HT-29 cells expressing COX1 and COX2 after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells expressing COX1 and COX2 after 24 hrs by MTT assay	[PMID: 22916316]
HT-29	IC₅₀	> 60 μM Compound: 3	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 24 hrs by MTT assay	[PMID: 26204233]
HUVEC	IC₅₀	5 mM Compound: Aspirin	Antiinflammatory activity in HUVEC assessed as inhibition of TNFalpha-induced ICAM1 expression measured after 6 hrs by FACS flow cytometry Antiinflammatory activity in HUVEC assessed as inhibition of TNFalpha-induced ICAM1 expression measured after 6 hrs by FACS flow cytometry	10.1039/C0MD00262C
Jurkat	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against human Jurkat cells expressing COX1 and COX2 after 24 hrs by MTT assay Cytotoxicity against human Jurkat cells expressing COX1 and COX2 after 24 hrs by MTT assay	[PMID: 22916316]
L02	IC₅₀	> 100 μM Compound: Aspirin	Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
LNCaP	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against human LNCAP cells after 24 hrs by MTT assay Cytotoxicity against human LNCAP cells after 24 hrs by MTT assay	[PMID: 22916316]
MCF7	IC₅₀	> 100 μM Compound: 1; ASA	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
MCF7	IC₅₀	> 50 μM Compound: Aspirin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
MCF7	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against human MCF7 cells expressing ER after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing ER after 24 hrs by MTT assay	[PMID: 22916316]
MDA-MB-231	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against ER deficient human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against ER deficient human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 22916316]
MDA-MB-231	IC₅₀	1510 μM Compound: Aspirin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23153797]
Mesenchymal stem cells	EC₅₀	> 300 μM Compound: ASA	Induction of adiponectin secretion in human differentiated BMMSC cells measured at 5 day in the presence of IDX induction medium by ELISA Induction of adiponectin secretion in human differentiated BMMSC cells measured at 5 day in the presence of IDX induction medium by ELISA	[PMID: 35172097]
MIA PaCa-2	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against COX deficient human MIAPaCa2 cells after 24 hrs by MTT assay Cytotoxicity against COX deficient human MIAPaCa2 cells after 24 hrs by MTT assay	[PMID: 22916316]
Microglia	IC₅₀	3.12 μM Compound: aspirin	Antineuroinflammatory activity in LPS-stimulated rat microglia cells assessed as inhibition of PMA-stimulated TXB2 release preincubated for 15 mins measured 70 mins after PMA challenge Antineuroinflammatory activity in LPS-stimulated rat microglia cells assessed as inhibition of PMA-stimulated TXB2 release preincubated for 15 mins measured 70 mins after PMA challenge	[PMID: 22153874]
PANC-1	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	7.45 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human PANC1 cells after 48 hrs by alamar blue assay Cytotoxicity against human PANC1 cells after 48 hrs by alamar blue assay	[PMID: 22494617]
PANC-1	IC₅₀	9.75 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human PANC1 cells after 24 hrs by alamar blue assay Cytotoxicity against human PANC1 cells after 24 hrs by alamar blue assay	[PMID: 22494617]
PC-3	IC₅₀	> 50 μM Compound: Aspirin	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
PC-3	IC₅₀	7.71 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human PC3 cells after 24 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 24 hrs by alamar blue assay	[PMID: 22494617]
PC-3	IC₅₀	7.82 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human PC3 cells after 48 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 48 hrs by alamar blue assay	[PMID: 22494617]
Platelet	IC₅₀	> 100 μM Compound: Aspirin	Inhibition of thrombin-induced human platelet aggregation by light transmission aggregometer Inhibition of thrombin-induced human platelet aggregation by light transmission aggregometer	[PMID: 18547115]
Platelet	IC₅₀	> 1000 μM Compound: ASA	Antiplatelet activity against collagen A23187-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method Antiplatelet activity against collagen A23187-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method	[PMID: 23425969]
Platelet	IC₅₀	> 1000 μM Compound: ASA	Antiplatelet activity against collagen ADP-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method Antiplatelet activity against collagen ADP-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method	[PMID: 23425969]
Platelet	IC₅₀	> 50 μg/mL Compound: Aspirin	Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry	[PMID: 21106454]
Platelet	IC₅₀	> 500 μM Compound: ASA	Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of ADP-induced aggregation by aggregometry Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of ADP-induced aggregation by aggregometry	[PMID: 25194932]
Platelet	IC₅₀	> 500 μM Compound: ASA	Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of U46619-induced aggregation by aggregometry Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of U46619-induced aggregation by aggregometry	[PMID: 25194932]
Platelet	IC₅₀	> 500 μM Compound: ASA	Antiplatelet activity against guinea pig platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation measured within 3 hrs by turbidimetric method Antiplatelet activity against guinea pig platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation measured within 3 hrs by turbidimetric method	[PMID: 22189137]
Platelet	IC₅₀	0.14 mM Compound: ASP	Antiplatelet aggregation activity in rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation incubated for 5 mins prior to arachidonic acid-challenge measured within 5 mins by Born's turbidimetric analysis Antiplatelet aggregation activity in rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation incubated for 5 mins prior to arachidonic acid-challenge measured within 5 mins by Born's turbidimetric analysis	[PMID: 23509954]
Platelet	IC₅₀	0.15 mM Compound: ASP	Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method	[PMID: 22827516]
Platelet	IC₅₀	0.88 mM Compound: ASP	Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet rich plasma by Born's turbidimetric method	[PMID: 22827516]
Platelet	IC₅₀	1.11 μM Compound: Aspirin	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method	[PMID: 30590258]
Platelet	IC₅₀	13.58 μg/mL Compound: Aspirin	Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry	[PMID: 21106454]
Platelet	IC₅₀	153.2 μM Compound: Aspirin	Inhibition of collagen-induced human platelet aggregation by light transmission aggregometer Inhibition of collagen-induced human platelet aggregation by light transmission aggregometer	[PMID: 18547115]
Platelet	IC₅₀	18 mg/kg Compound: Aspirin	Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	183 μM Compound: ASA	Antiplatelet activity against collagen collagen-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method Antiplatelet activity against collagen collagen-induced platelet aggregation in human plasma preincubated for 2 mins before addition of inducer by turbidimetric method	[PMID: 23425969]
Platelet	IC₅₀	20.3 μM Compound: aspirin	Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method	[PMID: 8988600]
Platelet	IC₅₀	20.6 μM Compound: aspirin	Antiplatelets aggregatory activity in human platelets rich plasma assessed as inhibition of collagen-induced platelets aggregation by aggregometry Antiplatelets aggregatory activity in human platelets rich plasma assessed as inhibition of collagen-induced platelets aggregation by aggregometry	[PMID: 19821574]
Platelet	IC₅₀	25 μM Compound: Aspirin	Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	27 μM Compound: Aspirin	Antiplatelet activity against washed rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge Antiplatelet activity against washed rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge	[PMID: 11374966]
Platelet	IC₅₀	30.5 μM Compound: Aspirin	Antiplatelet activity against rabbit platelet assessed as inhibition of collagen-induced platelet aggregation preincubated for 3 mins by turbidimetric method Antiplatelet activity against rabbit platelet assessed as inhibition of collagen-induced platelet aggregation preincubated for 3 mins by turbidimetric method	[PMID: 8759164]
Platelet	IC₅₀	31 μM Compound: Aspirin	Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	32.7 μM Compound: Aspirin	Antiplatelet activity against rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins by turbidimetric method Antiplatelet activity against rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins by turbidimetric method	[PMID: 8759164]
Platelet	IC₅₀	37.6 μM Compound: ASA	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method relative to control Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method relative to control	[PMID: 28453995]
Platelet	ED₅₀	4.5 mg/kg Compound: aspirin	Inhibition of bovine collagen-induced platelet aggregation isolated from po treated Hartley guinea pig after 1 hr treatment Inhibition of bovine collagen-induced platelet aggregation isolated from po treated Hartley guinea pig after 1 hr treatment	[PMID: 214552]
Platelet	IC₅₀	4.5 μM Compound: Acetylsalicylic acid	Antiplatelet activity in platelet rich plasma (unknown origin) assessed as inhibition of collagen-induced platelet aggregation incubated for 5 mins by aggregometer analysis Antiplatelet activity in platelet rich plasma (unknown origin) assessed as inhibition of collagen-induced platelet aggregation incubated for 5 mins by aggregometer analysis	[PMID: 37054760]
Platelet	IC₅₀	45 μM Compound: ASA	Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of arachidonic acid-induced aggregation by aggregometry Antiplatelet activity in guinea pig platelet rich plasma assessed as inhibition of arachidonic acid-induced aggregation by aggregometry	[PMID: 25194932]
Platelet	IC₅₀	45 μM Compound: ASA	Antiplatelet activity against guinea pig platelet-rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation measured within 3 hrs by turbidimetric method Antiplatelet activity against guinea pig platelet-rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation measured within 3 hrs by turbidimetric method	[PMID: 22189137]
Platelet	IC₅₀	5 μM Compound: Aspirin	Antiplatelet activity in human platelet-rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation treated for 5 mins prior to arachidonic acid challenge for 5 mins by turbidimetric method Antiplatelet activity in human platelet-rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation treated for 5 mins prior to arachidonic acid challenge for 5 mins by turbidimetric method	[PMID: 24859764]
Platelet	IC₅₀	54 μM Compound: 1, ASA	Antiaggregatory activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation preincubated for 10 mins before collagen challenge measured after 10 mins by aggregometry Antiaggregatory activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation preincubated for 10 mins before collagen challenge measured after 10 mins by aggregometry	[PMID: 21906954]
Platelet	IC₅₀	54 μM Compound: 1, ASA	Antiaggregatory activity in plasma rich human platelets assessed as inhibition of collagen-induced platelet aggregation preincubated for 10 mins before collagen challenge measured 10 mins after stimulus addition Antiaggregatory activity in plasma rich human platelets assessed as inhibition of collagen-induced platelet aggregation preincubated for 10 mins before collagen challenge measured 10 mins after stimulus addition	[PMID: 21688846]
Platelet	IC₅₀	58.9 μM Compound: Aspirin	Antiplatelet aggregation activity in New Zealand white rabbit platelet rich plasma assessed as inhibition of ADP-induced aggregation treated for 3 mins before ADP challenge by turbidimetric method Antiplatelet aggregation activity in New Zealand white rabbit platelet rich plasma assessed as inhibition of ADP-induced aggregation treated for 3 mins before ADP challenge by turbidimetric method	[PMID: 23394284]
Platelet	IC₅₀	6.07 μM Compound: Aspirin	Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation treated for 5 mins before ADP challenge measured for 6 mins by microplate reader Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation treated for 5 mins before ADP challenge measured for 6 mins by microplate reader	[PMID: 22137848]
Platelet	IC₅₀	7.07 μM Compound: Aspirin	Antiplatelet activity in New Zealand rabbit platelet-rich plasma assessed as inhibition of ADP-induced aggregation treated for 5 mins prior to ADP-challenge measured after 1 to 6 mins by spectrophotometric analysis Antiplatelet activity in New Zealand rabbit platelet-rich plasma assessed as inhibition of ADP-induced aggregation treated for 5 mins prior to ADP-challenge measured after 1 to 6 mins by spectrophotometric analysis	[PMID: 24565904]
Platelet	IC₅₀	7.7 μM Compound: ASA	Antiplatelet activity in human platelet-rich plasma assessed as inhibition of arachidonic acid-induced aggregation incubated for 5 mins prior to arachidonic acid-challenge measured for 3 mins by turbidrometric analysis Antiplatelet activity in human platelet-rich plasma assessed as inhibition of arachidonic acid-induced aggregation incubated for 5 mins prior to arachidonic acid-challenge measured for 3 mins by turbidrometric analysis	10.1007/s00044-013-0580-x
Platelet	IC₅₀	7.7 μM Compound: ASA	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 5 mins followed by arachidonic acid addition measured for 3 mins by aggregometric analysis Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 5 mins followed by arachidonic acid addition measured for 3 mins by aggregometric analysis	[PMID: 30108969]
Platelet	IC₅₀	7.76 μM Compound: Aspirin	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method	[PMID: 23639653]
Platelet	IC₅₀	75.4 μM Compound: Aspirin	Antiplatelet aggregatory activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation by aggregometry Antiplatelet aggregatory activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation by aggregometry	[PMID: 20056545]
Platelet	IC₅₀	80 μM Compound: ASA	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced aggregation preincubated for 10 mins before arachidonic acid challenge by aggregometry method Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced aggregation preincubated for 10 mins before arachidonic acid challenge by aggregometry method	[PMID: 22264757]
Platelet	IC₅₀	81 μM Compound: Acetylsalicylic acid	Antiplatelet activity in platelet rich plasma (unknown origin) assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins by aggregometer analysis Antiplatelet activity in platelet rich plasma (unknown origin) assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins by aggregometer analysis	[PMID: 37054760]
RAW264.7	IC₅₀	43.2 μM Compound: Aspirin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method	[PMID: 28561586]
SK-BR-3	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against ER deficient human SKBR3 cells after 24 hrs by MTT assay Cytotoxicity against ER deficient human SKBR3 cells after 24 hrs by MTT assay	[PMID: 22916316]
SK-BR-3	IC₅₀	6.93 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human SKBR3 cells after 48 hrs by alamar blue assay Cytotoxicity against human SKBR3 cells after 48 hrs by alamar blue assay	[PMID: 22494617]
SK-BR-3	IC₅₀	7.31 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human SKBR3 cells after 24 hrs by alamar blue assay Cytotoxicity against human SKBR3 cells after 24 hrs by alamar blue assay	[PMID: 22494617]
SW480	IC₅₀	> 5000000 nM Compound: ASA	Cytotoxicity against human SW480 cells expressing COX1 after 24 hrs by MTT assay Cytotoxicity against human SW480 cells expressing COX1 after 24 hrs by MTT assay	[PMID: 22916316]
U-251	EC₅₀	1341 μM Compound: 10	Antiproliferative activity against human U251MG cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human U251MG cells after 72 hrs by sulforhodamine B assay	[PMID: 30568753]
U-87MG ATCC	EC₅₀	723 μM Compound: 10	Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay	[PMID: 30568753]
UACC-903	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
UACC-903	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
UACC-903	IC₅₀	> 50 μM Compound: ASA	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
WI-38	IC₅₀	5.01 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human WI38 cells after 48 hrs by alamar blue assay Cytotoxicity against human WI38 cells after 48 hrs by alamar blue assay	[PMID: 22494617]
WI-38	IC₅₀	6.19 x 10^-4 M Compound: 1, ASA	Cytotoxicity against human WI38 cells after 24 hrs by alamar blue assay Cytotoxicity against human WI38 cells after 24 hrs by alamar blue assay	[PMID: 22494617]

體外研究
(In Vitro)

Aspirin 抑制人關(guān)節(jié)軟骨細(xì)胞中的 COX-1 和 COX-2，IC₅₀ 值分別為 3.57 μM 和 29.3 μM^[2]。
Aspirin acetylates COX-1 的絲氨酸 530，從而阻斷血小板中血栓素 A 的合成，減少血小板聚集^[3]。
Aspirin 通過(guò)干擾 CCAAT/增強(qiáng)子結(jié)合抑制 COX-2 蛋白表達(dá)蛋白質(zhì) beta (C/EBPbeta) 與其在 COX-2 啟動(dòng)子/增強(qiáng)子上的同源位點(diǎn)^[3]。
Aspirin 抑制 NF-κB 依賴(lài)性轉(zhuǎn)錄自 lgκ 增強(qiáng)子和人類(lèi)免疫缺陷病毒 (HIV) 轉(zhuǎn)染 T 細(xì)胞中的長(zhǎng)末端重復(fù)序列 (LTR)^[4]。
Aspirin 通過(guò)激活半胱天冬酶、激活 p38 MAP 激酶、釋放線粒體細(xì)胞色素 c、和神經(jīng)酰胺途徑的激活^[6]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Aspirin 可用于誘導(dǎo)胃腸潰瘍模型^[8]。

誘導(dǎo)胃腸潰瘍模型^[8]

致病原理

Aspirin 可抑制動(dòng)物內(nèi)源性前列腺素（PG）的合成。Aspirin 還能溶解粘膜上皮細(xì)胞的磷脂，導(dǎo)致粘膜通透性增加。

具體造模方法：

小鼠：白化病小鼠 • 雄性 • 6 周齡
給藥方式：500 mg/kg • oral • 單劑量

Note

造模成功指標(biāo)

組織學(xué)改變: 造成表皮上皮細(xì)胞的侵蝕。
導(dǎo)致粘膜厚度減少。
無(wú)COX-1反應(yīng)誘發(fā)潰瘍。

相關(guān)產(chǎn)品： /

拮抗產(chǎn)品： /

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male albino Charles River rats (200-250 g, 8 animals/group, fever was induced by 20 ml/kg of a 20 % aqueous suspension of brewer’s yeast which was injected SC in the back below the nape of the neck)^[7]
Dosage:	5, 25, 50, 100 and 150 mg/kg
Administration:	PO, once
Result:	Produced a statistically significant decrease of 0.23 ℃ at 15 min post-drug at the dose of 150 mg/kg. Antipyretic effect gradually increased in magnitude until a peak effect of 1.96 ℃ was reached at 120 min post-drug. The ED50 of aspirin was found to be 10.3 mg/kg with confidence limits of 1.8-23.0 mg/kg. The antipyretic response to aspirin is dependent on the dose of the compound administered.

Animal Model:	Albino male mice ^[8]
Dosage:	500 mg/kg, single dose
Administration:	oral
Result:	Caused erosion of the surface epithelial cells. Resulted in a decrease in the mucosal thickness. Induced ulcer without COX-1 reaction.

Clinical Trial

分子量

180.16

Formula

C₉H₈O₄

CAS 號(hào)

50-78-2

性狀

固體

顏色

White to off-white

中文名稱(chēng)

阿司匹林；乙酰水楊酸；鄰乙酰水楊酸

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

DMSO 中的溶解度 : 100 mg/mL (555.07 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開(kāi)封的 DMSO)

H₂O 中的溶解度 : 3.12 mg/mL (17.32 mM; ultrasonic and warming and heat to 37°C)

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	5.5507 mL	27.7533 mL	55.5065 mL
5 mM	1.1101 mL	5.5507 mL	11.1013 mL
10 mM	0.5551 mL	2.7753 mL	5.5507 mL

查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用。

* 備注：如您選擇水作為儲(chǔ)備液，請(qǐng)稀釋至工作液后，再用 0.22 μm 的濾膜過(guò)濾除菌后使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

方案一

請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (13.88 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (13.88 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請(qǐng)依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (13.88 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液，此方案實(shí)驗(yàn)周期在半個(gè)月以上的動(dòng)物實(shí)驗(yàn)酌情使用。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL玉米油中，混合均勻。

以下溶解方案，請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶。

方案一

請(qǐng)依序添加每種溶劑： Saline
Solubility: 5 mg/mL (27.75 mM); 澄清溶液; 超聲助溶
方案二

請(qǐng)依序添加每種溶劑： 50% PEG300 50% Saline
Solubility: 5 mg/mL (27.75 mM); 澄清溶液; 超聲助溶

動(dòng)物溶解方案計(jì)算器

請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只

由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量

請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購(gòu)。，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。

計(jì)算結(jié)果

工作液所需濃度 : mg/mL

儲(chǔ)備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。

動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過(guò)半月以上，請(qǐng)謹(jǐn)慎選擇該方案。

請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.82%

選擇批次：

Data Sheet (670 KB) SDS (392 KB)

COA (291 KB) LCMS (94 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and induciblecyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7. [Content Brief]

[2]. Blanco FJ, et al. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [Content Brief]

[3]. Wu KK, et al. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. [Content Brief]

[4]. Kopp E, et al. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994 Aug 12;265(5174):956-9. [Content Brief]

[5]. Burch JW, et al. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978 Feb;61(2):314-9. [Content Brief]

[6]. Elwood PC, et al. Aspirin, salicylates, and cancer. Lancet. 2009 Apr 11;373(9671):1301-9. [Content Brief]

[7]. Loux JJ, DePalma PD, Yankell SL. Antipyretic testing of aspirin in rats. Toxicol Appl Pharmacol. 1972 Aug;22(4):672-5. [Content Brief]

[8]. Yomna I Mahmoud, et al. Spirulina ameliorates aspirin-induced gastric ulcer in albino mice by alleviating oxidative stress and inflammation. Biomed Pharmacother. 2019. [Content Brief]

[9]. Zhongzhi Wang, et al. Protective Effects of Ginger against Aspirin-Induced Gastric Ulcers in Rats. Yonago Acta Med. 2011, 54, 1.

Aspirin 相關(guān)分類(lèi)

完整儲(chǔ)備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	5.5507 mL	27.7533 mL	55.5065 mL	138.7663 mL
	5 mM	1.1101 mL	5.5507 mL	11.1013 mL	27.7533 mL
	10 mM	0.5551 mL	2.7753 mL	5.5507 mL	13.8766 mL
	15 mM	0.3700 mL	1.8502 mL	3.7004 mL	9.2511 mL
DMSO	20 mM	0.2775 mL	1.3877 mL	2.7753 mL	6.9383 mL
	25 mM	0.2220 mL	1.1101 mL	2.2203 mL	5.5507 mL
	30 mM	0.1850 mL	0.9251 mL	1.8502 mL	4.6255 mL
	40 mM	0.1388 mL	0.6938 mL	1.3877 mL	3.4692 mL
	50 mM	0.1110 mL	0.5551 mL	1.1101 mL	2.7753 mL
	60 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL
	80 mM	0.0694 mL	0.3469 mL	0.6938 mL	1.7346 mL
	100 mM	0.0555 mL	0.2775 mL	0.5551 mL	1.3877 mL

* 備注：如您選擇水作為儲(chǔ)備液，請(qǐng)稀釋至工作液后，再用 0.22 μm 的濾膜過(guò)濾除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

產(chǎn)品名稱(chēng)：			* 需求量：
* 客戶(hù)姓名：			* Email：
* 電話：			* 公司或機(jī)構(gòu)名稱(chēng)：
留言給我們：

產(chǎn)品名稱(chēng)：			* Lot #：
* 客戶(hù)姓名：			* Email：
電話：			* 部門(mén)：
* 公司或機(jī)構(gòu)名稱(chēng)：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號(hào)-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營(yíng)業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Aspirin (Synonyms: 阿司匹林; Acetylsalicylic Acid; ASA)

Customer Review

Other Forms of Aspirin:

MCE 顧客使用本產(chǎn)品發(fā)表的 21 篇科研文獻(xiàn)

Aspirin 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 COX 亞型特異性產(chǎn)品:

查看 NF-κB 亞型特異性產(chǎn)品:

查看 Caspase 亞型特異性產(chǎn)品:

查看 p38 MAPK 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計(jì)算器

稀釋計(jì)算器

Aspirin 相關(guān)分類(lèi)

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門(mén)區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Aspirin (Synonyms: 阿司匹林; Acetylsalicylic Acid; ASA)

Customer Review

Other Forms of Aspirin:

Aspirin 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 21 篇科研文獻(xiàn)

Aspirin 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 COX 亞型特異性產(chǎn)品:

查看 NF-κB 亞型特異性產(chǎn)品:

查看 Caspase 亞型特異性產(chǎn)品:

查看 p38 MAPK 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

Aspirin 相關(guān)抗體:

摩爾計(jì)算器

稀釋計(jì)算器

Aspirin 相關(guān)分類(lèi)

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門(mén)區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z